Wafergen Biosystems Awarded $244,500 Grant Under Qualifying Therapeutic Discovery Project Program

WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced it has been awarded a $244,500 grant under the Qualifying Therapeutic Discovery Project program established under Section 48D of the Internal Revenue Code. The grant will aid the company in advancing its SmartChip genomic analysis platform for molecular identification of disease states and therapy selection.

Using the SmartChip system, researchers can better identify patient response, speeding the critical path for introducing new therapies and reducing U.S. health cares costs of both research and standard of care. The WaferGen SmartChip system identifies and validates gene expression patterns – biomarkers -- for multiple diseases. It uses the gold standard technique of quantitative real-time PCR in a high-density, nano-scale format. The SmartChip system enables the discovery and validation of higher quality biomarkers for improved genomics analysis in clinical analysis in clinical care settings, in addition to clinical trial patient stratification applications.

WaferGen's SmartChip biomarker discovery and validation capabilities can reduce long-term healthcare costs by improving the rate and cost-efficiency of therapeutic discovery and development, and by detecting optimal therapy selection for fewer adverse effects and expensive hospital visits. In identifying cancer therapies, researchers will need to understand causes at a molecular level, identify accurate/reliable biomarker signatures, and detect optimal therapeutic selection. The SmartChip system enables cost-effective genome-wide scans and focused oncology pathway and microRNA panels to address each of these critical needs.

The Qualifying Therapeutic Discovery Project is targeted at therapeutic discovery projects that show a reasonable potential to:

•Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions,
•Reduce the long-term growth of health care costs in the United States, or
•Significantly advance the goal of curing cancer within 30 years.

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries. The company currently offers the breakthrough SmartChip Real-Time PCR system, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The company believes that SmartChip is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing. In addition, the high throughput capabilities of the SmartChip system enable researchers to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.

Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, the SmartChip system is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip system. For additional information, please see http://www.wafergen.com.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    WaferGen Biosystems, Inc.. (2019, February 13). Wafergen Biosystems Awarded $244,500 Grant Under Qualifying Therapeutic Discovery Project Program. AZoNano. Retrieved on April 20, 2024 from https://www.azonano.com/news.aspx?newsID=20461.

  • MLA

    WaferGen Biosystems, Inc.. "Wafergen Biosystems Awarded $244,500 Grant Under Qualifying Therapeutic Discovery Project Program". AZoNano. 20 April 2024. <https://www.azonano.com/news.aspx?newsID=20461>.

  • Chicago

    WaferGen Biosystems, Inc.. "Wafergen Biosystems Awarded $244,500 Grant Under Qualifying Therapeutic Discovery Project Program". AZoNano. https://www.azonano.com/news.aspx?newsID=20461. (accessed April 20, 2024).

  • Harvard

    WaferGen Biosystems, Inc.. 2019. Wafergen Biosystems Awarded $244,500 Grant Under Qualifying Therapeutic Discovery Project Program. AZoNano, viewed 20 April 2024, https://www.azonano.com/news.aspx?newsID=20461.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.